Clinical Trials · NCT06083675

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

WithdrawnPhase 3Semaglutide (Prohibited)
Phase
Phase 3
Recruitment status
Withdrawn
Sponsor
Novo Nordisk A/S
Enrollment
0
Start date
Jan 2024
Locations
100 sites, 13 countries
Primary endpoint
Change in glycated haemoglobin (HbA1c)
View Semaglutide compound reference